For the quarter ending 2025-09-30, MBOT had $2,623K increase in cash & cash equivalents over the period. -$3,854K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,577 | -6,101 |
| Depreciation of property and equipment | 10 | 27 |
| Interest income and unrealized gains from marketable securities | 163 | 119 |
| Share-based compensation | 328 | 493 |
| Insurance recovery related to legal settlement and legal expenses received in cash | - | 0 |
| Prepaid expenses and other assets | 336 | -161 |
| Legal settlement paid in cash | - | 0 |
| Other payables and accrued liabilities | -103 | 92 |
| Proceeds from maturities of marketable securities | - | 0 |
| Net cash flows used in operating activities | -3,841 | -5,447 |
| Purchases of property and equipment | 13 | 22 |
| Purchases of marketable securities | 48,000 | 31,918 |
| Proceeds from sales of marketable securities | 3,301 | 5,801 |
| Net cash flows (used in) provided by investing activities | -44,712 | -26,139 |
| Issuance of common stock and warrants, net | 83,733 | 32,558 |
| Exercise of options | 1 | - |
| Net cash flows provided by financing activities | 51,176 | 32,558 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 2,623 | 972 |
| Cash and cash equivalents at beginning of period | 3,163 | - |
| Cash and cash equivalents at end of period | 6,758 | - |
Microbot Medical Inc. (MBOT)
Microbot Medical Inc. (MBOT)